Supernus FY 2024 rev $661.8M; Qelbree +72%; ONAPGO approved; SPN-820 Phase 2b fails

SUPERNUS PHARMACEUTICALS, INC.

2024-FY EPS reported $1.32 revenue$661,817,000

Full year 2024 revenue $661.8M (+9% YoY); Qelbree net sales $241.3M (+72%) and GOCOVRI $130.8M (+9%).
Full year 2024 operating earnings $81.7M vs loss of $(5.3)M in 2023; adjusted operating earnings $183.7M (+47%).
ONAPGO (apomorphine) FDA approved for advanced Parkinson's; launch planned in Q2 2025.
SPN-820 Phase 2b in treatment-resistant depression failed primary and secondary endpoints; program future under review.
FY 2025 guidance: total revenues $600-630M; adjusted operating earnings $105-130M, down from $183.7M in 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.